Editorial: Ct‐p13, a biosimilar of anti‐tumour necrosis factor‐alpha agent (infliximab), in inflammatory bowel diseases – authors’ reply

DOI: 10.1111/apt.14060

,

Issn Print: 0269-2813

Publication Date: 2017/05/01

Editorial: CT‐P13, a biosimilar of anti‐tumour necrosis factor‐alpha agent (infliximab), in inflammatory bowel diseases – authors’ reply

Y. Komaki; A. Yamada; F. Komaki; D. Micic; A. Ido; A. Sakuraba

Author Information: Section of Gastroenterology, Hepatology and Nutrition


		Checking for direct PDF access through Ovid

View on Journal Site

Abstract unavailable for this article.


		Loading Related Articles